Developing a policy for second-generation antipsychotic drugs

Health Affairs

Volumn 28, Issue 5, 2009, Pages

  Rosenheck, Robert A ^a   Sernyak, Michael J ^b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; GENERIC DRUG; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; DRUG COST; HEALTH CARE POLICY; HUMAN; METABOLIC DISORDER; PATIENT EDUCATION; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; UNITED STATES; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH POLICY; HUMANS; SCHIZOPHRENIA; UNITED STATES;

EID: 70349221152     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.28.5.w782     Document Type: Article

References (59)

1. E.Q. Wu et al., "The Economic Burden of Schizophrenia in the United States in 2002," Journal of Clinical Psychiatry 66, no.9 (2005): 1122-1129. (Pubitemid 41442278)
2. M.E. Domino and M.S. Swartz, "Who Are the New Users of Antipsychotic Medication?" Psychiatric Services 59, no.5 (2008): 507-514.
3. D. Buono, "IMS Study Finds Decline in Prescription Drug Market Growth," Drug Store News, 21 April 2008, http://findarticles.com/p/ articles/mi-m3374/is-5-30/ai-n25407255?tag=artBody;c011 (accessed 1 July 2009).
4. M. Duggan, "Do New Prescription Drugs Pay for Themselves? The Case of Second-Generation Antipsychotics," Journal of Health Economics 24, no.1 (2005): 1-31.
5. R.A. Rosenheck, D.L. Leslie, and J.A. Doshi, "Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making," Psychiatric Services 59, no.5 (2008): 515-520.
6. R.G. Frank, "Policy toward Second-Generation Antipsychotic Drugs: A Cautionary Note," Psychiatric Services 59, no.5 (2008): 521-522.
7. D.L. Van Brunt et al., "Outpatient Use of Major Antipsychotic Drugs in Ambulatory Care Settings in the United States, 1997-2000," Medscape Psychiatry and Mental Health, 1 August 2003, http://www.medscape.com/ viewarticle/458984-1 (accessed 15 August 2008).
8. J.M. Davis, N. Chen, and I.D. Glick, "A Meta-Analysis of the Efficacy of Second-Generation Antipsychotics," Archives of General Psychiatry 60, no.6 (2003): 553-564.
9. M. Percudani, C. Barbui, and M. Tansella, "Effect of Second-Generation Antipsychotics on Employment and Productivity in Individuals with Schizophrenia: An Economic Perspective," Pharmaco Economics 22, no.11 (2004): 701-718.
10. Regarding risperidone, see R. Farley, "Drug Research: To Test or to Tout?" St. Petersburg Times, 12 April 2008.
11. Regarding olanzapine, see R.A. Rosenheck, "The Growth of Psychopharmacology in the 1990s: Evidence-based Practice or Irrational Exuberance, " International Journal of Law and Psychiatry 28, no.5 (2005): 467-483.
12. A Berenson, "Eli Lilly Said to Encourage Use of Pill for Unapproved Uses," New York Times, 18 December 2006.
13. R. Rosenheck et al., "Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia: A Randomized Controlled Trial," Journal of the American Medical Association 290, no.20 (2003): 2693-2702. (Pubitemid 37475597)
14. R.A. Rosenheck, "Efficacy vs. Effectiveness of Second-Generation Antipsychotics: Haloperidol without Prophylactic Anticholinergics as a Comparator," Psychiatric Services 56, no.1 (2005): 85-92;
15. and S.A. Barnes et al., "Impact of Missing Data and How It Is Handled on the Rate of False-Positive Results in Drug Development," Pharmaceutical Statistics 7, no.3 (2008): 215-225.
16. J.A. Lieberman et al., "Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia," New England Journal of Medicine 353, no.12 (2005): 1209-1223;
17. R.A. Rosenheck et al., "Cost-Effectiveness of Second- Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia," American Journal of Psychiatry 163, no.12 (2006): 2080-2089;
18. R.S. Keefe et al., "Neurocognitive Effects of Antipsychotic Medications in Patients with Chronic Schizophrenia in the CATIE Trial,"Archives of General Psychiatry 64, no.6 (2007): 633-647;
19. S.G. Resnick et al., "Employment Outcomes in a Randomized Trial of Second-Generation Antipsychotics and Perphenazine in the Treatment of Individuals with Schizophrenia," Journal of Behavioral Health Services and Research 35, no.2 (2008): 215-225;
20. J.W. Swanson et al., "Comparison of Antipsychotic Medication Effects on Reducing Violence in People with Schizophrenia," British Journal of Psychiatry 193, no.1 (2008): 37-43;
21. and D. Miller et al., "Extrapyramidal Side Effects of Second Generation Antipsychotics in a Randomised Trial," British Journal of Psychiatry 193, no.4 (2008): 279-288.
22. R.A. Rosenheck et al., "Changing Perspectives on Second-Generation Antipsychotics: Reviewing the Cost-Effectiveness Component of the CATIE Trial," Expert Review of Pharmacoeconomics and Outcomes Research 7, no.2 (2007): 103-111.
23. P.B. Jones et al., "Randomized Controlled Trial of Effect on Quality of Life of Second-Generation versus First-Generation Antipsychotic Drugs in Schizophrenia-Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)," Archives of General Psychiatry 63, no.10 (2006): 1079-1087.
24. L. Sikich et al., "Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-Affective Disorder: Findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study," American Journal of Psychiatry 165, no.11 (2008): 1421-1431.
25. J.M. Kane et al., "Aripiprazole for Treatment-Resistant Schizophrenia: Results of a Multicenter, Randomized, Double-Blind, Comparison Study versus Perphenazine," Journal of Clinical Psychiatry 68, no.2 (2007): 213-223. (Pubitemid 46362642)
26. American Diabetes Association et al., "Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes," Diabetes Care 27, no.2 (2004): 596-601.
27. C.U. Correll, S. Leucht, and J.M. Kane, "Lower Risk for Tardive Dyskinesia Associated with Second-Generation Antipsychotics: A Systematic Review of One-Year Studies," American Journal of Psychiatry 161, no.3 (2004): 414-425.
28. Miller et al., "Extrapyramidal Side Effects."
29. S.W. Woods et al., " Incidence of Tardive Dyskinesia with Atypical and Conventional Antipsychotic Medications" Journal of Clinical Psychiatry (forthcoming);
30. and Rosenheck et al., "Second-Generation Antipsychotics."
31. W.T. Carpenter and R.W. Buchanan, "Lessons to Take Home from CATIE," Psychiatric Services 59, no.5 (2008): 523-525.
32. D. Polsky et al., "Clinical Trial-Based Cost-Effectiveness Analyses of Antipsychotic Use," American Journal of Psychiatry 163, no.12 (2006): 2047-2056.
33. Rosenheck et al., "Cost-Effectiveness of Second-Generation Antipsychotics."
34. L.M. Davies et al., "Cost-Effectiveness of First- Versus Second-Generation Antipsychotic Drugs: Results from a Randomised Controlled Trial in Schizophrenia Responding Poorly to Previous Therapy," British Journal of Psychiatry 191 (2007): 14-22.
35. D.L. Leslie and R.A. Rosenheck, "Off-Label Use of Antipsychotic Medications in the Department of Veterans Affairs" (Unpublished paper, New England Mental Illness, Education, and Clinical Center, 2009).
36. Agency for Healthcare Research and Quality, Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics, Comparative Effectiveness Review no. 6, January 2007, http://effectivehealthcare.ahrq.gov/ repFiles/Atypical-Antipsychotics-Final-Report.pdf (accessed 1 July 2008).
37. Domino and Swartz, "Who Are the New Users?"
38. J.M. Kane, "Commentary on the Clinical Antipsychotic Trials of Intervention Effectivenenss (CATIE)," Journal of Clinical Psychiatry 76, no.5 (2006):831-832;
39. and H.Y. Meltzer and W.V. Bobo, "Interpreting the Efficacy Findings in the CATIE Study: What Clinicians Should Know," CNS Spectrum 11, no.7, Supp. 7 (2006): 14-24.
40. R. Ganguli and M. Strassnig, "Are Older Antipsychotic Drugs Obsolete?," British Medical Journal 332, no.7554 (2006): 1346-1347.
41. S. Sharfstein, "Antipsychotics, Economics, and the Press," Psychiatric News 40, no.23 (2005): 3.
42. T.A.Moore et al., "The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2006 Update," Journal of Clinical Psychiatry 68, no.11 (2007): 1751-1762.
43. J. Parks et al., "Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008: Translating Knowledge to Promote Individualized Treatment," Schizophrenia Bulletin Advance Access, 2 April 2008, http://schizophreniabulletin.oxfordjournals.org/cgi/reprint/sbn019 (accessed 25 May 2008).
44. Carpenter and Buchanan, "Lessons to Take Home from CATIE."
45. Parks et al., "Principles of Antipsychotic Prescribing."
46. N.H. Covell, M.T. Finnerty, and S.M. Essock, "Implications of CATIE for Mental Health Services Researchers," Psychiatric Services 59, no.5 (2008): 526-529;
47. and K. Duckworth and M.J. Fitzpatrick, "NAMI Perspective on CATIE: Policy and Research Implications," Psychiatric Services 59, no.5 (2008): 537-539.
48. M.J. Sernyak and R.A. Rosenheck, "Antipsychotic Use in the Treatment of Outpatients with Schizophrenia in the VA from Fiscal Years 1999 to 2006," Psychiatric Services 59, no.5 (2008): 567-569;
49. and E. Cascade and A. Kalali, "Use of Antipsychotics Pre- and Post Dissemination of the CATIE Data," Psychiatry 4, no.5 (2007): 21-23.
50. J. Hoadley, Cost Containment Strategies for Prescription Drugs: Assessing the Evidence in the Literature, March 2005, http://www.kff.org/rxdrugs/7295.cfm (accessed 12 March 2008).
51. R.A. Rosenheck et al., "Rethinking Antipsychotic Formulary Policy," Schizophrenia Bulletin 34, no.2 (2008): 375-380.
52. S.B. Soumerai et al., "Use of Atypical Antipsychotic Drugs for Schizophrenia in Maine Medicaid Following a Policy Change," Health Affairs 27, no.3 (2008): w185-w195 (published online 1 April 2008; 10.1377/hlthaff.27.3. w185);
53. M.R. Law, D. Ross-Degnan, and S.B. Soumerai, "Effect of Prior Authorization on Second-Generation Antipsychotic Agents on Pharmacy Utilization and Reimbursements," Psychiatric Services 59, no.5 (2008): 540-546;
54. and R.A. Rosenheck, "Evidence of Adverse Effect of PA Policy In Maine Is Weak," Health Affairs online letters, 9 April 2008, http://content.healthaffairs.org/cgi/eletters/hlthaff.27.3.w185v1#3455 (accessed 1 July 2009).
55. N.Daniels and J. Sabin, Setting Limits Fairly: Can We Learn to Share Medical Resources? (New York:Oxford, 2003).
56. D.P. Goldman, G.F. Joyce, and Y. Zheng, "Prescription Drug Cost Sharing: Associations with Medication and Medical Utilization and Spending and Health," Journal of the American Medical Association 298, no.1 (2007): 61-69. (Pubitemid 47026771)
57. See the broad advocacy program for counter-detailing spearheaded by the Prescription Project at http://www.prescriptionproject.org. The published research on counter-detailing includes S.B. Soumerai and J. Avorn, "Principles of Educational Outreach ('Academic Detailing') to Improve Clinical Decision Making," Journal of the American Medical Association 263, no.4 (1990):549-556;
58. MA O'Brien et al., "Educational Outreach Visits: Effects on Professional Practice and HealthCare Outcomes," Cochrane Database of Systematic Reviews 4 (2007): CD000409;
59. and J. Avorn et al., "A Randomized Trial of a Program to Reduce the Use of Psychoactive Drugs in Nursing Homes," New England Journal of Medicine 327, no.3 (1992): 168-173.